Quick Answer
Seres Therapeutics, Inc. reported R&D Expense of $49.06 million for fiscal year 2025.
Seres Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $49.06M | -24.1% |
| 2024 | $64.60M | -45.1% |
| 2023 | $117.60M | +7.2% |
| 2022 | $109.65M | -22.7% |
| 2021 | $141.89M | +56.7% |
| 2020 | $90.57M | +13.0% |
| 2019 | $80.14M | -16.5% |
| 2018 | $95.95M | +7.3% |
| 2017 | $89.45M | +9.1% |
| 2016 | $81.99M | +115.2% |
| 2015 | $38.09M | +255.4% |
| 2014 | $10.72M | +123.1% |
| 2013 | $4.80M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $12.62M | -23.4% | -2.5% |
| June 30, 2025 | $12.94M | -18.1% | +9.5% |
| March 31, 2025 | $11.82M | -39.4% | -28.2% |
| September 30, 2024 | $16.46M | -34.6% | +4.1% |
| June 30, 2024 | $15.81M | -66.2% | -18.9% |
| March 31, 2024 | $19.49M | -55.7% | -22.5% |
| September 30, 2023 | $25.15M | -41.7% | -46.2% |
| June 30, 2023 | $46.79M | +6.5% | +6.4% |
- Seres Therapeutics, Inc. showed a decrease of -24.1% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, Seres Therapeutics, Inc.’s r&d expense has grown by 921.0% (from $4.80 million to $49.06 million).
- The most recent figure is from Seres Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: